Foresight Diagnostics announced an oral presentation in partnership with University Health Network's (UHN) Princess Margaret Cancer Centre at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer on September 6-9, 2025, in Barcelona, Spain.
The presentation featured analysis of MRD performance in a cohort of stage I lung cancer patients from the ctDNA-Lung DETECT study using Foresight CLARITY.
Foresight CLARITY demonstrated high ctDNA-MRD detection rates at both pre- and post-operative timepoints. Highlights include:
Pre-operative MRD detection was 68% and post-operative MRD detection was 38%.
Clinical sensitivity for relapse detection at post-surgical landmark was 55%, with a median lead time of 10 months prior to clinical recurrence.
Post-operative MRD detection was significantly associated with worse recurrence-free survival (RFS) at both post-operative landmark (HR = 3.14, p = 0.0425) and at the one-year timepoint (HR = 8.20, p = 0.0001).
